Phcog.Net logo
Submit

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Journal of Pharmacology and PharmacotherapeuticsNOW IN
    Article

    Belatacept: Good, but not good enough?

    Sreejith Parameswaran1★, R. P. Swaminathan1★ Corresponding author

    1. 1Updating the Beers Criteria for potentially inappropriate medication use in older adults: Results of a US consensus panel of experts. Arch Intern Med 2003;163:2716-24. 3. O’Mahony D, Gallagher PF. Inappropriate prescribing in the older population: Need for new criteria. Age Ageing 2008;37:138-41. [Downloaded free from http://www.jpharmacol.com on Wednesday, October 13, 2021, IP: 157.45.222.78].

    CORRESPONDENCE

    Sreejith Parameswaran

    Updating the Beers Criteria for potentially inappropriate medication use in older adults: Results of a US consensus panel of experts. Arch Intern Med 2003;163:2716-24. 3. O’Mahony D, Gallagher PF. Inappropriate prescribing in the older population: Need for new criteria. Age Ageing 2008;37:138-41. [Downloaded free from http://www.jpharmacol.com on Wednesday, October 13, 2021, IP: 157.45.222.78].

    sreejith@jipmer.net

    Volume 3, Issue 1 · pp. 82–83 · PUBLISHED 2012 · DOI: 10.4103/0976-500X.92510

    View on J Pharmacol. Pharmacother. original site ↗

    ABSTRACT

    Belatacept has brought about a ‘paradigm shift’ in the maintenance immunosuppression after solid organ transplantation, in that it is the first biologic agent approved for use for long-term maintenance immunosuppression for solid organ transplantation. Biologic agents (Basiliximab, thymoglobulin, etc.) already have an established role as induction immunosuppressive agents at the time of kidney transplantation but there are several issues to be tackled before a biologic agent can be accepted as a viable option for long-term maintenance immunosuppression. Such an agent should inhibit the immune system in a nondepleting manner without creating excessive immunodeficiency, should not have initial and prolonged immunogenicity, should not require therapeutic drug monitoring, and should offer an acceptable administration route and interval between doses. Belatacept satisfies all these requirements, except that it requires intravenous (IV) administration.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Parameswaran, S., & Swaminathan, R. P. (2012). Belatacept: Good, but not good enough?. Journal of Pharmacology and Pharmacotherapeutics, 3(1), 82–83. https://doi.org/10.4103/0976-500X.92510